Hadensa Ointment

Quick links to important sections

Hadensa Ointment

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hadensa Ointment

Hadensa Ointment is structurally defined as a multi-component topical pharmaceutical preparation intended for external use. Its purpose is the localized relief of discomfort, achieved through a synergistic combination of active substances.

Property Description
Active Ingredients Lignocaine Hydrochloride, Menthol, Thymol
Form Ointment (Semi-solid preparation)
Pharmacological Class Local Anesthetic, Counterirritant, Anti-infective combination
Common Use Symptomatic relief of local discomfort
Origin Combination of synthetic and naturally derived compounds

What is the Identity and Class of Hadensa Ointment?

Hadensa Ointment is classified as an anorectal preparation, a specialized type of dermatological agent specifically formulated for application to the perianal region. It is recognized as a combination medicine utilizing multiple active substances for synergistic effects at the application site. Its distinctive feature is the ointment dosage form, which, unlike creams or gels, ensures prolonged contact with the skin and forms a persistent protective layer. The product's intended action is exclusively localized via the topical route of administration, a method utilized for managing localized symptoms.

What are the Active Ingredients and Composition of the Ointment?

The preparation is formulated with three principal active ingredients: Lignocaine Hydrochloride, Menthol, and Thymol. Lignocaine Hydrochloride is a synthetic amino amide compound classified as a local anesthetic. Menthol, a naturally derived terpene, is integral to the formulation, producing a cooling sensation that acts as a counterirritant on the skin's surface. These active compounds are suspended within the fatty base, typically Lanolin, which enhances patient comfort by providing a protective, emollient barrier.

What is the General Function and Purpose of the Combination?

The combination of ingredients means the general function is to provide rapid and temporary symptomatic relief. This multimodal action combines local numbing, cooling, and surface protection, offering a solution for localized discomforts, such as anal irritation. The preparation's purpose is to manage associated symptoms like pain, burning, and itching. The formulation is clinically recognized for its ability to target and manage these multiple symptoms simultaneously, enhancing patient comfort without addressing the underlying pathological condition itself.

Regulatory References

  1. MedlinePlus: Lignocaine Topical

What side effects are possible with Hadensa Ointment?

Official Safety Profile and Adverse Reactions

The safety profile for this multi-component topical preparation is classified into local reactions at the application site and potential systemic effects arising from the absorption of the active local anesthetic component, Lignocaine. The information is derived from official regulatory documentation.

Most Common Adverse Reactions are typically localized reactions, primarily classified as Skin and Subcutaneous Tissue Disorders. These effects include redness, swelling, and irritation at the site of application. Serious skin burns are noted as a rare but documented adverse effect associated with topical products containing the counterirritant component, Menthol.


Serious Adverse Reactions and Systemic Risk

Systemic adverse reactions are generally rare and are linked to high plasma concentrations of Lignocaine resulting from excessive dosage or short intervals between applications. These potential systemic risks primarily involve the Nervous System and the Cardiovascular System. Serious adverse reactions officially documented include convulsions, cardiovascular collapse, and cardiac arrest. Additionally, the rare but life-threatening blood disorder Methemoglobinemia is cited as a potential risk associated with local anesthetics.


Population-Specific Safety Considerations

Official labeling mandates specific caution for populations with increased susceptibility to systemic effects. These groups include elderly, acutely ill, and debilitated patients. Infants, particularly those under six months of age, are noted to be at increased risk for developing Methemoglobinemia. Risk of absorption is also higher when the product is applied to traumatized mucosa or in the presence of sepsis, defining a key safety constraint.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Hadensa Ointment is defined by the official regulatory profile of its active local anesthetic component. Systemic toxicity may occur if excessive amounts are absorbed, potentially manifesting in two major documented syndromes. This profile outlines required actions based on government guidance.

Documented Manifestations and Serious Outcomes

Initial signs of systemic toxicity often involve the Central Nervous System (CNS) and may include lightheadedness, confusion, dizziness, tinnitus, metallic taste, or tremors. These may progress to more severe symptoms such as seizures, unconsciousness, or respiratory arrest. Cardiovascular effects are also officially documented, including bradycardia (slow heart rate), hypotension, and ultimately cardiovascular collapse. A separate, serious outcome is Methemoglobinemia, signaled by cyanosis (pale, blue skin), headache, and shortness of breath.

Mandatory Emergency Actions

Immediate medical attention must be sought if any signs of systemic toxicity or Methemoglobinemia are observed. The regulatory guidance mandates that immediate treatment is required to avert life-threatening cardiovascular or CNS complications. Management of severe reactions may necessitate resuscitative equipment and supportive care. A specific antidote, Methylene blue, is officially documented for the treatment of severe Methemoglobinemia. Patients who are elderly, acutely ill, or have severe hepatic disease are noted to be at increased risk of developing toxic concentrations.

Therapeutic Uses of Hadensa Ointment

Main Uses of Hadensa Ointment

Hadensa ointment is a topical medication formulated to manage symptoms associated with various anorectal conditions. It is primarily utilized for the relief of discomfort caused by hemorrhoids and related inflammatory issues of the anal region.

Hemorrhoids (Piles)

Hadensa is most commonly used for both internal and external hemorrhoids. It addresses the physical manifestations of the condition by providing a cooling sensation and helping to reduce the swelling of hemorrhoidal tissues. This application is intended to manage the irritation and fullness often experienced by patients.

Anal Fissures

The ointment is also used in cases of anal fissures, which are small tears in the lining of the anal canal. In this context, the preparation helps to soothe the affected area and manage the localized pain that occurs during and after bowel movements.

Anal Pruritus

Anal pruritus, or persistent itching in the anal area, is another condition for which Hadensa is used. The ingredients work to calm the skin and provide a protective barrier, reducing the urge to scratch and preventing further irritation of the delicate tissue.

Benefits and Physiological Effects

The benefits of Hadensa ointment are derived from its combination of active components that provide multifaceted relief from anorectal distress.

  • Symptomatic Pain Relief: The formulation contains local anesthetic properties that help to dull sharp pain and persistent aching in the rectal area.
  • Reduction of Inflammation: It assists in decreasing the localized edema and inflammation of the mucous membranes, which can help shrink swollen veins.
  • Cooling and Soothing Effect: The inclusion of menthol provides an immediate cooling sensation, which is particularly effective at neutralizing burning sensations and heat associated with acute flare-ups.
  • Antiseptic Action: The ointment contains ingredients that offer mild antiseptic properties, which help maintain hygiene in the affected area and support the natural recovery process of the skin.

Regulatory References

  1. Health Canada Anorectal Drug Products Labelling Standard

Eligibility and Restrictions for Use

The eligibility profile for Hadensa Ointment is defined by regulatory standards governing its active ingredients, primarily the local anesthetic Lignocaine. Use is restricted or prohibited based on specific patient populations and pre-existing conditions.

Populations Who Must Not Use the Medicine (Contraindications)

  • Individuals with a known allergy or hypersensitivity to Lignocaine Hydrochloride, Menthol, Thymol, or any other component of the ointment.
  • Application is strictly prohibited on traumatized or broken mucosa or in the presence of a secondary bacterial infection at the site.

Populations Requiring Conditional Use

  • Age-Group Eligibility: Unconditioned use is established for adults and adolescents (age 12 and older). For children under 12 years of age, use is conditional and requires consultation with a health professional, as unconditioned use is not established for this group.
  • Maternal Status: Pregnant or breastfeeding individuals must consult a health professional prior to use, as required by official regulatory labeling.
  • Systemic Conditions: Use requires caution and may be restricted in patients with severe hepatic (liver) impairment or certain severe cardiovascular conditions (such as heart block or severe shock), due to the potential for altered systemic effects. Reduced dosage may also be advised for acutely ill or elderly patients.

What should I know about interactions with other medicines?

Hadensa Ointment Interactions with other medicines and products

This section outlines interactions officially documented in government regulatory sources, based on the profile of its active ingredient, Lignocaine. All systemic interactions are contingent on the degree of absorption following topical application.

Documented Pharmacological Interactions

Interaction Type Interacting Categories/Substances Regulatory Statement Classification
Pharmacodynamic Reinforcement Other Local Anesthetics and Class I Antiarrhythmic drugs (e.g., Mexiletine) Additive risk of systemic toxic effects on cardiac function.
Pharmacodynamic Reinforcement Drugs associated with Methemoglobinemia (e.g., Nitrites) Increased risk of developing Methemoglobinemia.
Pharmacokinetic Alteration CYP3A4 Inhibitors (e.g., Cimetidine) Reduced Lignocaine clearance, which may increase plasma concentrations.

Interaction-Related Restrictions and Considerations

The official regulatory profile includes specific constraints regarding administration and patient health status:

  • Procedural Constraint: Government labeling advises against the concurrent application of external heat sources (such as heating pads) directly to the application area, as this interaction is documented to increase systemic drug exposure.
  • Population Note: Patients with severe hepatic disease are noted to be at a greater risk of reaching toxic blood concentrations from interactions that affect clearance, due to impaired liver metabolism.

Mechanism of Action

The physiological mechanism of Hadensa Ointment involves the synergistic modulation of peripheral nervous system excitability and local tissue factors by its active components. The local anesthetic Lignocaine acts via reversible blockade of voltage-gated sodium channels ( Nav) on sensory nerve fibers. This interaction prevents the influx of Na^+ ions, thereby halting the generation and propagation of electrical signals (action potentials), resulting in a localized, reversible suppression of peripheral nerve excitability. Concurrently, Menthol functions as an agonist on the TRPM8 receptor (cold and menthol receptor), a specialized ion channel in sensory neurons. This TRPM8 activation generates a competitive input to the sensory system, resulting in a physiological shift in local sensory perception. The third component, Thymol, contributes by exerting an antimicrobial and anti-inflammatory mechanism through disruption of the bacterial cell membrane and modulation of local inflammatory pathways, influencing the physiological state of local tissue factors (microbial integrity and inflammatory mediator release) that perpetuate an excitatory state.

Dosage and Administration Information

Instruction Map: Official Administration Guidelines

The usage of Hadensa Ointment adheres to standardized protocols for topical anorectal local anesthetics, ensuring appropriate delivery of the multi-component formulation. The designated route of administration is strictly topical for external and localized anorectal application.

Administration Scope

The standard dosing schedule involves the application of a thin layer to the affected area, with the maximum allowed frequency typically set at up to three or four times daily during periods of acute symptoms. The timing of application is contextual and is often specified to occur relative to defecation (e.g., before and after) rather than meal times.

Before administration, the application site must be cleansed and gently dried as a necessary preparation requirement. The use of the preparation is generally restricted to a short-term course for temporary symptomatic management and is not intended for prolonged daily use.

Age-Group Administration Rules

Specific rules govern use in certain populations. For pediatric patients (typically under 12 years of age), the dose and duration of use must be determined and supervised by a healthcare professional due to specialized considerations regarding systemic absorption.

Connection to the Overall Use Protocol

The official protocol defines a structured, localized delivery system requiring adherence to strict topical/anorectal route and cleansing preconditions. The established limits on frequency and the constraint of short-term use define a standardized pattern for intermittent application, strictly confining the medication’s use to temporary, acute symptomatic periods.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hadensa Ointment


Evidence for Symptom Study related to Haemorrhoids

The research record includes observational studies and reviews that have explored the use of multi-component preparations in the study of symptoms related to haemorrhoids. These studies were used in research exploring how symptoms change over time and focused on adult subjects with conditions characterized by fluctuating or episodic manifestations. Research has examined patient-reported outcomes describing perceived discomfort, such as pain, itching (pruritus), and burning sensation, with measurements typically taken using standardized scales.

Studies monitored changes during the study period, particularly during phases of heightened symptom activity. Findings describe patterns observed in the studies where patients reported changes in their symptom intensity during the study period. These patterns is generally consistent with prior observations of the local anesthetic component.

Evidence is limited by a relative lack of large-scale, well-controlled comparative trials specifically for the triple-ingredient combination. Comparative evidence is lacking to definitively show how the full formulation was evaluated against a simple inactive preparation (placebo) or against a single active ingredient. The evidence contributes to understanding symptom patterns but does not provide individual predictions based on the group patterns observed in these studies.


Evidence for Study of Anal Fissure Discomfort

The preparation was studied for its application in the study of symptoms related to anal fissure discomfort. This evidence primarily stems from Randomized Controlled Trials (RCTs) and systematic reviews that focused on the effect of the primary analgesic ingredient, Lignocaine, often applied in research contexts involving fluctuating or unstable symptoms. Studies explored outcomes related to physical discomfort, specifically the level of pain, and also monitored anal fissure healing rate via clinical inspection over defined time intervals.

Research highlights changes measured during the study period, indicating that the local anesthetic component studies reported findings related to changes in pain levels, which reflects an outcome measured in studies of that ingredient. Studies focusing on episodes where symptoms become more noticeable described patterns in reported discomfort levels.

Research on the combination's role in measured fissure healing rates remains insufficient. The evidence for the combination's role in healing remains limited. Furthermore, the results apply only to the populations studied, which were primarily adults with acute fissures, not those with chronic, complex presentations.

Key Studies & References

  1. Lidocaine Topical: MedlinePlus Drug Information
  2. Health Canada Anorectal Drug Products Labelling Standard

Frequently Asked Questions (FAQ)

Common questions about Hadensa Ointment (FAQ)


Q: Is Hadensa Ointment a steroid medicine?

According to the official product profile, the active ingredients are classified as a local anesthetic (Lignocaine), a counterirritant (Menthol), and an anti-infective (Thymol) combination. This formulation does not contain an ingredient classified as a corticosteroid or steroid.

Q: How quickly can I expect to notice anything after using Hadensa Ointment?

Studies related to the active local anesthetic component, Lignocaine, indicate an onset of action that typically begins within three to five minutes following correct topical application. This means you may notice the numbing effect starting soon after using the ointment.

Q: Is it safe to use Hadensa Ointment if I am taking blood thinners?

Official product warnings state that consultation with a health professional is specified if you are taking any prescription drug, including potent categories like blood thinners, before using this product. This caution is in place due to the potential for systemic effects or interactions that only a healthcare provider can assess.

Q: Does Hadensa Ointment have any ingredient that could show up in a drug test?

Lidocaine (Lignocaine) is an amide anesthetic, which is chemically distinct from typical drugs of abuse. Research has indicated that neither lidocaine nor its primary metabolite, norlidocaine, are known to typically cause false-positive results on standard cocaine urine immunoassay screens.

Q: Is the sensation of burning or stinging normal when applying Hadensa Ointment?

Official labeling lists irritation at the application site as one of the most common adverse reactions. While the Menthol component is intended to produce a cooling sensation, if a significant or prolonged burning sensation occurs, contact with a health professional is specified by the label.

Q: Do I need a prescription for Hadensa Ointment in the U.S.?

Lidocaine-containing preparations intended for anorectal use, generally up to 5% concentration, are typically classified by the FDA as an Over-the-Counter (OTC) Human Drug Product. This means a prescription is generally not required for purchase.

Q: Is it possible for Hadensa Ointment to interact with supplements or vitamins?

Official warnings indicate that consultation with a health professional is specified if you are taking any prescription drug. While specific interactions with most supplements are not detailed, official documents highlight the need for careful consideration, especially with products that can affect liver enzyme activity, such as certain CYP3A4 inhibitors.

Q: Is Hadensa Ointment available as a cream or a suppository as well?

The official product documentation defines this preparation structurally and exclusively as an Ointment, which is a semi-solid topical dosage form. The label does not provide information about this specific formulation being available in other forms like a cream or suppository.

Q: What should I do if a child accidentally swallows Hadensa Ointment?

The official label mandates keeping the product out of the reach and sight of children at all times. If accidental ingestion occurs, the official label specifies contacting a poison control center or seeking emergency medical help immediately due to the potential for systemic absorption of the ingredients.

Q: Can I use Hadensa Ointment if I have diabetes?

The official warning specifies that consultation with a health professional is appropriate if you have certain systemic conditions. While diabetes is not always explicitly listed, patients with co-morbidities are generally at higher risk for Methemoglobinemia from the active ingredient, and these factors indicate that professional consultation is warranted prior to use.

Q: Are there any known major food interactions with Hadensa Ointment?

Specific food interactions are generally not listed for topical products due to low absorption. However, some sources on the active ingredient (Lidocaine) note that certain foods, like grapefruit juice, can affect the liver enzymes (CYP3A4) that process the drug.

Q: Is it possible to develop a tolerance to Hadensa Ointment over time?

Regulatory documents indicate that repeated doses can potentially lead to significant increases in the amount of the drug in the bloodstream due to accumulation. This factor is consistent with the need to adhere to the short-term use guidelines established in the product label.

Q: Does Hadensa Ointment have ingredients that cause skin thinning?

Skin thinning (atrophy) is a known side effect typically associated with topical corticosteroids (steroids). Since this product is officially classified as a local anesthetic combination and not a steroid, this specific risk is not listed as a contraindication.

Q: Can I use Hadensa Ointment if I have high blood pressure?

The regulatory warning indicates that consultation with a health professional is specified before use if you are presently taking a prescription drug for high blood pressure or depression. This is due to the potential for interactions that affect the body's cardiovascular system.

Q: Are there any restrictions on driving or operating machinery while using Hadensa Ointment?

Systemic absorption from correct topical use is typically low. Labeling for similar topical preparations indicates that use of the product is generally not expected to affect ability to drive or operate machinery.

Q: What are the signs that Hadensa Ointment is starting to work?

The primary expected signs that the local anesthetic component is taking effect are the reduction in pain, burning, or itching sensations at the site of application. The onset of the numbing effect is typically within 3 to 5 minutes.

Q: What is the difference between an ointment and a cream like Hadensa?

The product is defined as an ointment, which uses a fatty base like Lanolin or Petrolatum. This base creates a persistent, protective, and emollient barrier that remains on the skin’s surface for a long time, unlike a cream, which is generally more water-based and absorbed more quickly.

Q: Do regulatory bodies classify Hadensa Ointment as safe for general use?

The product’s classification as an Over-the-Counter (OTC) drug for its approved symptomatic uses means regulatory bodies have deemed it generally recognized as safe and effective (GRASE). This classification is based on the use of the product being consistent with the label's instructions and warnings.

Q: Why is it important not to use Hadensa Ointment for extended periods?

The product is intended for short-term use only, which is specified for a short duration. Prolonged use is warned against because it can increase the absorption of the active ingredients into the bloodstream, potentially leading to systemic adverse effects.

Q: Do official prescribing documents mention use in patients with kidney or liver issues?

The official profile explicitly notes that patients with severe hepatic (liver) impairment are at a greater risk of reaching toxic blood concentrations. Official documents also mention the need for careful consideration for patients with renal (kidney) dysfunction due to potential metabolite accumulation.

Q: Why might a doctor suggest Hadensa Ointment instead of a suppository?

The ointment is formulated for topical (external) application to the perianal region to create a protective, soothing barrier. A doctor might suggest an ointment over a suppository (which is inserted for internal effect) if the patient’s primary symptoms, such as itching and burning, are mainly localized to the external area.

Q: What does official research say about the effectiveness of Hadensa Ointment?

Official research and studies examine the use of this and similar multi-component preparations in managing patient-reported symptoms like pain and itching related to anorectal discomfort. The studies observed patterns where patients reported a change in symptom intensity, which is consistent with the expected action of the local anesthetic ingredient.

Q: Can I use Hadensa Ointment if I have a known allergy to other skin products?

The official contraindication (must not be used) applies only to individuals with a known allergy or hypersensitivity to the product's specific active ingredients (Lignocaine, Menthol, Thymol) or any of its inactive components. Allergies to unrelated skin products do not constitute a specific contraindication.

Q: What is the recommended maximum duration of use for Hadensa Ointment?

The preparation is generally restricted to a short-term course for temporary symptomatic management. The use is generally restricted to a short-term course, as specified in the official documents.

Q: Can Hadensa Ointment be used for other types of rectal discomfort?

In addition to haemorrhoid-related symptoms, the preparation is also studied for use with discomfort related to anal fissures. Its general purpose is the localized relief of common symptoms like pain, burning, and itching in the anorectal region.

Q: Does Hadensa Ointment have an expiration date?

Yes, Hadensa Ointment does have a defined expiration date. Official disposal instructions refer to the procedure for when the product is expired, confirming that the manufacturer determines an expiration date to ensure the product’s quality and potency.

Q: What are the inactive ingredients in Hadensa Ointment?

The active compounds are suspended within a fatty base, which is composed of inactive ingredients. The base typically includes an emollient like Lanolin or Petrolatum, along with other inactive stabilizers and preservative agents required to maintain the ointment's texture and stability.

Q: Does the efficacy of Hadensa Ointment vary between different age groups?

Official regulatory warnings note that certain patient groups, such as older (elderly) patients, or those who are acutely ill, are at a higher risk of systemic side effects due to potential differences in absorption and metabolism. These factors may indirectly influence the overall safety and response profile of the medicine.

How should Hadensa Ointment be stored and disposed of?

How to Store and Dispose of Hadensa Ointment

Official regulatory guidelines define specific conditions for storing and disposing of Hadensa Ointment to maintain the product's quality.

Storage Requirements

The ointment must be stored in a cool and dry place at a temperature below 30°C (Store below 30°C). It is mandatory to keep the container tightly closed and protect the product from direct sunlight and freezing, as the ointment must not be frozen.

For safety, Hadensa Ointment must always be stored out of the reach and sight of children, in accordance with official labeling for all topical medicines.

Disposal Instructions

When the product is expired or unused, disposal must follow local pharmaceutical waste guidelines. The medicine must not be flushed down the toilet or poured into wastewater systems. The officially recommended method is to dispose of the product through an established drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hadensa Ointment found in:

A-Z Index: